+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Precision Medicine Market by Technology, by Sequencing Technology, Product Application End User - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4612767
  • Report
  • Region: Global
  • 150 pages
  • Allied Analytics LLP
1 of 4
Precision medicine is personalized healthcare model exclusively designed for an individual. The procedure considers various factors affecting patient such as environment, lifestyle, and individual variability in genes. Most suitable medical therapies are constructed depending upon primary diagnosis of disease and patient’s genomic framework. The global precision medicine market accounted for $3,516 million in 2016, and is estimated to reach at $7,746 million by 2023, registering a CAGR of 11.9% from 2017 to 2023.

Precision medicine allows doctors and researchers to estimate specific medications that work best against a particular type of disease in a set group of people. Similar therapeutic treatments are then carried out in case of people responding to the treatments with a positive outlook. Which excludes patients showing side effects or any unwanted results regarding treatment.

Government initiatives and huge investment by private companies into R&D drive the precision medicine market. Moreover, growth in aging population and rise in global incidences of cancer are anticipated to boost the market growth. Application of high throughput genomic technologies in biomedical research and therapeutic procedures accelerate market progression.

The precision medicine market is segmented based on technology, sequencing technology, product, applications, and geography. Based on technology, it is divided into genomics, transcriptomics and epigenomics. Based on sequencing technology, the market is bifurcated into sequencing by synthesis, ion semiconductor sequencing, sequencing by ligation, pyrosequencing, single molecule real time sequencing, chain termination sequencing and nanopore sequencing. Based on product, the precision medicine market is subdivided into consumables, instruments and services.

Based on applications, it is classified into oncology, CNS, immunology, respiratory medicine, infections, and other applications. Based on end users, it is categorized into diagnostic tool companies, pharma & biotech companies, clinical laboratories, and healthcare IT/big data companies. Geographically, it is analyzed based on four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS

The study provides an in-depth analysis of the global precision medicine market and the current trends and future estimations to elucidate the imminent investment pockets.
The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders capitalize on the prevailing market opportunities.
Extensive analysis of the market based on sequencing technology assists to understand the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Precision Medicine Market Segments:

By Technology

Genomics
Transcriptomics
Epigenomics

By Sequencing Technology

Sequencing by Synthesis
Ion Semiconductor Sequencing
Sequencing by Ligation
Pyrosequencing
Single Molecule Real Time Sequencing
Chain Termination Sequencing
Nanopore Sequencing

By Product

Consumables
Instruments
Services

By Application

Oncology
CNS
Immunology
Respiratory Medicine
Infections
Others Applications

By End user

Diagnostic Tool companies
Pharma & Biotech Companies
Clinical Laboratories
Healthcare IT/ Big Data Companies

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Taiwan
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. TOP PLAYER POSITIONING
3.4. PATENTS ANALYSIS
3.4.1. Patent analysis by year
3.4.2. Patent analysis by region
3.5. PORTERS FIVE FORCES ANALYSIS
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.2. Restraints
3.6.3. Opportunities

CHAPTER 4 GLOBAL PRECISION MEDICINE MARKET, BY TECHNOLOGY
4.1. OVERVIEW
4.1.1. Market size & forecast
4.2. GENOMICS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size & forecast
4.3. TRANSCRIPTOMICS
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size & forecast
4.4. EPIGENOMICS
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size & forecast

CHAPTER 5 GLOBAL PRECISION MEDICINE MARKET, BY SEQUENICNG TECHNOLOGY
5.1. OVERVIEW
5.1.1. Market size & forecast
5.2. SEQEUNCING BY SYNTHESIS (SBS)
5.2.1. Market size & forecast
5.3. ION SEMICONDUCTOR SEQUENCING (ISS)
5.3.1. Market size & forecast
5.4. SEQEUNCING BY LIGATION (SBL)
5.4.1. Market size & forecast
5.5. PYROSEQUENCING
5.5.1. Market size & forecast
5.6. SINGLE MOLECULE REAL TIME SEQUENCING (SMRT)
5.6.1. Market size & forecast
5.7. NANOPORE SEQUENCING
5.7.1. Market size & forecast

CHAPTER 6 GLOBAL PRECISION MEDICINE MARKET, BY PRODUCT
6.1. OVERVIEW
6.1.1. Market size & forecast
6.2. CONSUMABLES
6.2.1. Key market trends
6.2.2. Growth factors and opportunities
6.2.3. Market size & forecast
6.3. INSTRUMENTS
6.3.1. Key market trends
6.3.2. Growth factors and opportunities
6.3.3. Market size & forecast
6.4. SERVICES
6.4.1. Key market trends
6.4.2. Growth factors and opportunities
6.4.3. Market size & forecast

CHAPTER 7 GLOBAL PRECISION MEDICINE MARKET, BY APPLICATION
7.1. OVERVIEW
7.1.1. Market size & forecast
7.2. ONCOLOGY
7.2.1. Market size & forecast
7.3. CENTRAL NERVOUS SYSTEM (CNS)
7.3.1. Market size & forecast
7.4. IMMUNOLOGY
7.4.1. Market size & forecast
7.5. RESPIRATORY MEDICINE
7.5.1. Market size & forecast
7.6. INFECTION
7.6.1. Market size & forecast
7.7. OTHER APPLICATION
7.7.1. Market size & forecast

CHAPTER 8 GLOBAL PRECISION MEDICINE MARKET, BY END USERS
8.1. OVERVIEW
8.1.1. Market size & forecast
8.2. PHARMA & BIOTECH COMPANIES
8.2.1. Market size & forecast
8.3. DIAGNOSTIC TOOL COMPANIES
8.3.1. Market size & forecast
8.4. HEALTHCARE IT/ BIG DATA COMPANIES
8.4.1. Market size & forecast
8.5. CLINICAL LABORATORIES
8.5.1. Market size & forecast

CHAPTER 9 GLOBAL PRECISION MEDICINE MARKET, BY GEOGRAPHY
9.1. OVERVIEW
9.2. NORTH AMERICA
9.2.1. Key market trends
9.2.2. Key growth factors and opportunities
9.2.3. Market size & forecast
9.2.3.1. U.S. market size and forecast
9.2.3.2. Canada market size and forecast
9.2.3.3. Mexico market size and forecast
9.3. EUROPE
9.3.1. Key market trends
9.3.2. Key growth factors and opportunities
9.3.3. Market size & forecast
9.3.3.1. Germany market size and forecast
9.3.3.2. France market size and forecast
9.3.3.3. UK market size and forecast
9.3.3.4. Italy market size and forecast
9.3.3.5. Spain market size and forecast
9.3.3.6. Rest of Europe market size and forecast
9.4. ASIA-PACIFIC
9.4.1. Key market trends
9.4.2. Key growth factors and opportunities
9.4.3. Market size & forecast
9.4.3.1. Japan market size and forecast
9.4.3.2. China market size and forecast
9.4.3.3. Australia market size and forecast
9.4.3.4. India market size and forecast
9.4.3.5. South Korea market size and forecast
9.4.3.6. Taiwan market size and forecast
9.4.3.7. Rest of Asia-Pacific market size and forecast
9.5. LAMEA
9.5.1. Key market trends
9.5.2. Key growth factors and opportunities
9.5.3. Market size & forecast
9.5.3.1. Brazil market size and forecast
9.5.3.2. Turkey market size and forecast
9.5.3.3. Saudi Arabia market size and forecast
9.5.3.4. Rest of LAMEA market size and forecast

CHAPTER 10 COMPANY PROFILES
10.1. ILLUMINA, INC
10.1.1. Operating business segments
10.1.2. Business performance
10.1.3. Key strategic moves and developments
10.2. THERMO FISHER SCIENTIFIC, INC
10.2.1. Operating business segments
10.2.2. Business performance
10.2.3. Key strategic moves and developments
10.3. ROCHE HOLDING AG (ROCHE)
10.3.1. Operating business segments
10.3.2. Business performance
10.3.3. Key strategic moves and developments
10.4. LABORATORY CORPORATION OF AMERICA HOLDINGS (LCAH)
10.4.1. Operating business segments
10.4.2. Business performance
10.4.3. Key strategic moves and developments
10.5. QUEST DIAGNOSTICS (QD)
10.5.1. Operating business segments
10.5.2. Business performance
10.5.3. Key strategic moves and developments
10.6. QIAGEN N.V.,
10.6.1. Operating business segments
10.6.2. Business performance
10.6.3. Key strategic moves and developments
10.7. ASTRAZENECA
10.7.1. Operating business segments
10.7.2. Business performance
10.7.3. Key strategic moves and developments
10.8. NOVARTIS AG (NAG)
10.8.1. Operating business segments
10.8.2. Business performance
10.8.3. Key strategic moves and developments
10.9. BRISTOL-MYERS SQUIBB (BMS)
10.9.1. Operating business segments
10.9.2. Business performance
10.9.3. Key strategic moves and developments
10.10. ELI LILLY & COMPANY (ELC)
10.10.1. Operating business segments
10.10.2. Business performance
10.10.3. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, Precision Medicine Market by Technology, Application and End User: Global Opportunity Alysis and Industry Forecast, 2017-2023," the global precision medicine market accounted for $3,516 million in 2016, and is estimated to reach at $7,746 million by 2023, registering a CAGR of 11.9% from 2017 to 2023. North America was the highest contributor in the precision medicine market in 2016; however, Asia-Pacific is anticipated to witness a highest growth rate throughout the forecast period.

Precision medicine is novel approach toward disease treatment in healthcare, medications are customized based on patients persolized healthcare needs such as, influence of genes & surrounding environment on patients health and result of various tests carried out on various levels. Follow-up on tests and treatment can be planned based on response of the patients toward treatment, which reduces side effects of drug and multiple administration of medications.

The precision medicine market is expected to grow at a productive rate the during forecast period. Surge in global incidence of cancer and increase in aging population susceptible to diseases are expected to boost the demand of precision medicines. Government initiatives & grants and private companies investing in R&D of precision medicines boost the market growth. However, strict regulation set by governments and risk associated with sharing genetic data of patients impedes the growth of precision medicine market.

Drug discovery generated the highest revenue in 2016, and is anticipated to continue this trend in the future. The requirement of quality drugs and versatile therapies for treatment is expected to boost the growth of this segment. Gene sequencing grows at a surprising rate and is expected to continue to grow during the forecast period.

North America holds the highest market share in 2016 owing to high prevalence rate of cancer and modern healthcare facilities. Moreover, adoption of experimental medicines and growth in awareness about precision medicines is expected to boost the North America market. However, Asia-pacific region is expected to grow at the highest CAGR during the forecast period considering, swift industrialization in the area, increase in disposable income, and upsurge in government initiatives to modernize healthcare infrastructure.

Key findings of the Precision Medicine Market:

The sequencing by synthesis segment is projected to grow at the highest CAGR during the alysis period.
Consumables segment generated the highest revenue and is expected to continue its domince in future.
North America domited the market and is projected to grow at a CAGR of 11.0%.
Chi is expected to grow at the highest CAGR of 16.8% in Asia-Pacific.
The epigenomics segment is anticipated to grow at the highest CAGR of 14.1% during the forecast period.

The key companies profiled in the report include Roche Holding AG, Illumi Inc., Thermo Fisher Scientific Inc., QIAGEN, Quest Diagnostics, Laboratory Corporation of America Holdings, Novartis AG, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly & Company.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll